BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 17636537)

  • 21. Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study.
    Lonneux M; Hamoir M; Reychler H; Maingon P; Duvillard C; Calais G; Bridji B; Digue L; Toubeau M; Grégoire V
    J Clin Oncol; 2010 Mar; 28(7):1190-5. PubMed ID: 20124179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical values for abnormal ¹⁸F-FDG uptake in the head and neck region of patients with head and neck squamous cell carcinoma.
    Lee HS; Kim JS; Roh JL; Choi SH; Nam SY; Kim SY
    Eur J Radiol; 2014 Aug; 83(8):1455-60. PubMed ID: 24929443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathology and FDG PET correlation of residual lymph nodes in head and neck cancer after radiation treatment.
    Yao M; Luo P; Hoffman HT; Chang K; Graham MM; Menda Y; Tan H; Buatti JM
    Am J Clin Oncol; 2007 Jun; 30(3):264-70. PubMed ID: 17551303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDG-PET and detection of distant metastases and simultaneous tumors in head and neck squamous cell carcinoma: a comparison with chest radiography and chest CT.
    Krabbe CA; Pruim J; van der Laan BF; Rödiger LA; Roodenburg JL
    Oral Oncol; 2009 Mar; 45(3):234-40. PubMed ID: 18715818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck.
    Ng SH; Yen TC; Chang JT; Chan SC; Ko SF; Wang HM; Lee LY; Kang CJ; Wong AM; Liao CT
    J Clin Oncol; 2006 Sep; 24(27):4371-6. PubMed ID: 16983105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer.
    Ong SC; Schöder H; Lee NY; Patel SG; Carlson D; Fury M; Pfister DG; Shah JP; Larson SM; Kraus DH
    J Nucl Med; 2008 Apr; 49(4):532-40. PubMed ID: 18344440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
    Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Results of pretherapeutic lymph node diagnosis in head and neck tumors. Clinical value of 18-FDG positron emission tomography (PET)].
    Di Martino E; Nowak B; Krombach GA; Sellhaus B; Hausmann R; Cremerius U; Büll U; Westhofen M
    Laryngorhinootologie; 2000 Apr; 79(4):201-6. PubMed ID: 10838683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation of efficacy and clinical impact of positron emission tomography with 18F fluoro-deoxyglucose in patients with suspicion of recurrent head and neck cancer or distant metastases].
    Alvarez Pérez RM; Borrego Dorado I; Ruiz Franco-Baux JV; Vázquez Albertino RJ
    Rev Esp Med Nucl; 2007; 26(1):30-9. PubMed ID: 17286946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of gamma-PET in the evaluation of patients with recurrent squamous cell cancer of the head and neck.
    Goshen E; Yahalom R; Talmi YP; Rotenberg G; Oksman Y; Zwas ST
    Int J Oral Maxillofac Surg; 2005 Jun; 34(4):386-90. PubMed ID: 16053847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 18FDG-PET for the assessment of primary head and neck tumors: clinical, computed tomography, and histopathological correlation in 38 patients.
    Paulus P; Sambon A; Vivegnis D; Hustinx R; Moreau P; Collignon J; Deneufbourg JM; Rigo P
    Laryngoscope; 1998 Oct; 108(10):1578-83. PubMed ID: 9778305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High incidence of chest malignancy detected by FDG PET in patients suspected of recurrent squamous cell carcinoma of the upper aerodigestive tract.
    Perlow A; Bui C; Shreve P; Sundgren PC; Teknos TN; Mukherji SK
    J Comput Assist Tomogr; 2004; 28(5):704-9. PubMed ID: 15480048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current status of FDG-PET for head and neck cancer.
    Wong RJ
    J Surg Oncol; 2008 Jun; 97(8):649-52. PubMed ID: 18493944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. (18)F-FDG PET/CT surveillance at 3-6 and 12 months for detection of recurrence and second primary cancer in patients with head and neck squamous cell carcinoma.
    Kim JW; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Br J Cancer; 2013 Dec; 109(12):2973-9. PubMed ID: 24149172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient.
    Lonneux M; Lawson G; Ide C; Bausart R; Remacle M; Pauwels S
    Laryngoscope; 2000 Sep; 110(9):1493-7. PubMed ID: 10983949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers.
    Andrade RS; Heron DE; Degirmenci B; Filho PA; Branstetter BF; Seethala RR; Ferris RL; Avril N
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1315-22. PubMed ID: 16750327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Staging of head and neck tumors: [18F]fluorodeoxyglucose positron emission tomography compared with physical examination and conventional imaging modalities.
    Sigg MB; Steinert H; Grätz K; Hugenin P; Stoeckli S; Eyrich GK
    J Oral Maxillofac Surg; 2003 Sep; 61(9):1022-9. PubMed ID: 12966477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined PET/CT-perfusion in patients with head and neck cancers might predict failure after radio-chemotherapy: a proof of concept study.
    Pietsch C; de Galiza Barbosa F; Hüllner MW; Schmid DT; Haerle SK; Huber GF; Studer G; Hany TF; Veit-Haibach P
    BMC Med Imaging; 2015 Dec; 15():60. PubMed ID: 26714448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.